Ansell Limited

Ansell reported adjusted EPS of $0.663 for the half. Organic constant-currency sales fell 0.6%, but after adjusting for $27 million of prior-year temporary order favorability and backorder clearance, adjusted sales growth was 2.1%. GPADE margin improved 220 basis points year over year, EBIT margin rose 180 basis points to 14.3%, and EBIT grew 15.4% organically. SG&A increased 0.4% organically, significant items were $7.3 million, the effective tax rate was 24.1%, working capital was down about $23 million versus June 2025, net CapEx was $28 million, and $47 million of shares were repurchased. Management maintained full-year adjusted EPS guidance of $1.37 to $1.49 and said the business is absorbing about $80 million of annualized U.S. tariff cost through pricing and mitigation; it also flagged about a $5 million full-year FX headwind, with roughly $1.5 million in H1 and $3.5 million in H2.

Neil Salmon framed the quarter as evidence that Ansell now has stronger foundations: more disciplined operations, better customer alignment, and a broader set of growth levers. He emphasized the success of the digital transformation, APIP-driven organizational changes, and service differentiation through Guardian and related tools, saying these capabilities support long-term shareholder value. His tone was confident and reflective, with repeated emphasis that the company is better positioned now than in the past.

Brian Montgomery focused on margin expansion, cash generation, and balance-sheet strength. He highlighted the 220 basis point improvement in GPADE margin, citing lower air freight, sourcing savings, and about $6 million of KBU synergies in the half, while noting tariff-related pricing was modestly dilutive to GPADE margin rate. He also pointed to strong cash conversion of 112%, working capital down about $23 million, $28 million of net CapEx, $47 million of buybacks, and net debt to EBITDA improving to 1.5x despite the repurchase program.

Analysts pressed management on tariff pass-through, demand elasticity, and whether competitors could undercut Ansell after price increases. Management said customer acceptance has been generally good, price increases are already in market, and any volume leakage has been limited to more commoditized or ancillary products, mainly in medical exam. Questions also focused on subdued end markets, cleanroom destocking tied to the Kimberly-Clark acquisition, and whether Scientific or mature-market growth can sustain the longer-term 3% to 5% organic growth framework; management said mature markets outperformed expectations, cleanroom destocking is mostly identifiable and partly behind them, and Scientific remains a higher-growth opportunity, especially in manufacturing environments rather than lab work.